2025年05月22日 星期四 首页   |   期刊介绍   |   编 委 会   |   投稿指南   |   期刊订阅   |   广告合作   |   联系我们   |   ENGLISH
哈尔滨医药  2024, Vol. 44 Issue (4): 27-30    DOI: 10.3969/j.issn.1001-8131.2024.04.008
  论著 本期目录 | 过刊浏览 | 高级检索 |
布托啡诺对男性经尿道膀胱肿瘤切除术后导尿管相关膀胱刺激征的影响
殷凤伟, 陈梦婷, 徐成飞, 程亮
蚌埠市第三人民医院麻醉科,安徽 蚌埠233000
The Effect of Butorphanol on Urinary Tract Related Bladder Irritation Signs after Male Transurethral Bladder Tumor Resection
Yin Fengwei, Chen Mengting, Xu Chengfei, Cheng Liang
Anesthesiology Department of the Third People's Hospital of Bengbu City,Bengbu,Anhui 233000
全文: PDF (538 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨布托啡诺对男性经尿道膀胱肿瘤切除术(transurethral resection of bladder tumor,TURBT)后导尿管相关膀胱不适(catheter-related bladder discomfort,CRBD)的影响。方法 选取择期全身麻醉下行TURBT的男性患者68例,年龄≥20岁且≤80岁,ASA分级Ⅰ~Ⅲ级,手术时间30~120min。采用在线随机化软件生成的随机数表将患者分为两组布托啡诺组(B组)34例和对照组(C组)34例。C组采用舒芬太尼+生理盐水麻醉诱导,B组采用舒芬太尼+布托啡诺0.02mg/kg麻醉诱导。记录并比较:①记录两组患者拔管后即刻(T0)、术后1h(T1)、术后2h(T2)以及术后6h(T3)CRBD发生例数、程度;②记录两组患者曲马多及舒芬太尼用量;记录两组患者麻醉后监测治疗室(Postanesthesia care unit,PACU)停留时间;③记录两组患者镇静水平以及头晕、恶心、呕吐的发生率。结果 B组患者在T0、T1、T2以及T3时刻CRBD发生的例数以及严重程度均少于C组,差异有统计学意义(P<0.05)。B组患者因中重度CRBD进行曲马多补救用量明显低于C组,差异有统计学意义(P<0.01)。B组患者在PACU停留时间少于C组,差异有统计学意义(P<0.05)。两组患者舒芬太尼镇痛补救用量,PACU内的镇静水平,发生头晕、恶心及呕吐等不良反应的情况差异无统计学意义(P>0.05)。结论 布托啡诺可以明显降低TBRBT术后的CRBD的发生率和严重程度,且无明显不良反应,可安全有效地用于缓解CRBD。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
殷凤伟
陈梦婷
徐成飞
程亮
关键词 布托啡诺男性经尿道膀胱肿瘤切除术导尿管相关膀胱不适    
AbstractObjective Exploring the effect of butorphanol on catheter-related bladder discomfort(CRBD)after transurethral resection of bladder tumor(TURBT)in males.Methods 68 male patients aged ≥20y and ≤80 years old who underwent TURBT under selective general anesthesia were selected,with ASA grades I to Ⅲ and surgery time ranging from 30 minutes to 120 minutes.Using a random number table generated by online randomization software,patients were divided into two groups:a butorphanol group(Group B)of 34 cases and a control group(Group C)of 34 cases.Group C received anesthesia induction with sufentanil and physiological saline,while Group B received anesthesia induction with sufentanil and butorphanol at a dose of 0.02 mg/kg.Record and compare:①Record the number and degree of CRBD occurrences immediately after extubation(T0),1 hour after surgery(T1),2 hours after surgery(T2),and 6 hours after surgery(T3)in two groups of patients;②Record the dosage of tramadol and sufentanil for two groups of patients;Record the duration of stay in the Postanesthesia care unit(PACU)after anesthesia for two groups of patients;③Record the sedation levels and incidence of dizziness,nausea,and vomiting in two groups of patients.Results The number and severity of CRBD occurrence in Group B patients at T0,T1,T2,and T3 were lower than those in Group C,and the difference was statistically significant(P<0.05).The amount of tramadol used for salvage treatment in Group B patients with moderate to severe CRBD was significantly lower than that in Group C,and the difference was statistically significant(P<0.01).The duration of stay in PACU in Group B was shorter than that in Group C,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the amount of sufentanil used for pain relief,the level of sedation within the PACU,and the occurrence of adverse reactions such as dizziness,nausea,and vomiting between the two groups of patients(P>0.05).Conclusion Butorphanol can significantly reduce the incidence and severity of CRBD after TBRBT surgery,and there are no significant adverse reactions.It can be safely and effectively used to alleviate CRBD.
Key wordsButorphanol    Male    Transurethral resection of bladder tumor    Catheter-related bladder discomfort
收稿日期: 2024-04-16     
PACS:  R737.14  
引用本文:   
殷凤伟, 陈梦婷, 徐成飞, 程亮. 布托啡诺对男性经尿道膀胱肿瘤切除术后导尿管相关膀胱刺激征的影响[J]. 哈尔滨医药, 2024, 44(4): 27-30.
Yin Fengwei, Chen Mengting, Xu Chengfei, Cheng Liang. The Effect of Butorphanol on Urinary Tract Related Bladder Irritation Signs after Male Transurethral Bladder Tumor Resection. journal1, 2024, 44(4): 27-30.
链接本文:  
http://www.hrbyybjb.org.cn/CN/10.3969/j.issn.1001-8131.2024.04.008     或     http://www.hrbyybjb.org.cn/CN/Y2024/V44/I4/27
版权所有 © 《哈尔滨医药》编辑部  备案号: 黑ICP备19005758号-1
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn